Ultragenyx Pharmaceutical (NASDAQ:RARE) Earns Overweight Rating from Cantor Fitzgerald
Cantor Fitzgerald reiterated their overweight rating on shares of Ultragenyx Pharmaceutical (NASDAQ:RARE – Free Report) in a research report report published on Wednesday, Benzinga reports. The firm currently has a $115.00 price target on the biopharmaceutical company’s stock. Other analysts also recently issued reports about the company. The Goldman Sachs Group raised Ultragenyx Pharmaceutical from […]
More Stories
Social Security Agency Announces Correction of Tens of Millions of Files
By Zachary Stieber Federal officials announced on Oct. 20 that they corrected tens of millions of Social Security records, including...
Virginia Senator L. Louise Lucas Charged With Federal Drug Trafficking, Money Laundering
By Jack Phillips Federal prosecutors charged Democratic Virginia state Sen. L. Louise Lucas on Thursday with allegedly leading a criminal...
France Bans Illegitimate Protest Groups as Macron Blames Far-Left for Riots
By Rachel Roberts French President Emmanuel Macron said Thursday that “illegitimate” protests would be banned in the coming days and...
Ilhan Omar Says Threats Forcing Her to Move Home After Federal Agents Searched DC Apartment
By Guy Birchall Rep. Ilhan Omar (D-Minn.) says she will have to move out of her Washington apartment due to...
SBA Refers Nearly 700 Businesses for Government Audits Over Potential Fraud
By Naveen Athrappully The Small Business Administration (SBA) has referred 689 companies that were removed from a federal program to...
Late October Is the Best Time to Buy – Especially in Midterm Election Years
By Louis Navellier In the first half of October, the S&P 500 was basically flat, while the NASDAQ is off...